Insamo is at the forefront of drug discovery, focusing on the development of membrane-permeable and orally available cyclic peptides. The company employs an innovative platform that automates the processes of designing, synthesizing, and testing potential drug candidates at an unprecedented scale. This approach allows Insamo to leverage trillions of proprietary experimental data points, enabling rapid iteration of their design cycle. By exploring an extensive chemical space that is drug-like, Insamo aims to set a new standard in the application of scalable machine learning techniques to drug design, ultimately transforming the way drugs are discovered for challenging diseases.

The company's mission-driven strategy emphasizes the importance of addressing some of the most difficult medical challenges through advanced technology. Insamo's unique capabilities in drug design not only enhance the efficiency of the discovery process but also aim to improve the overall success rate of developing effective therapeutics. With a dedicated team and a commitment to innovation, Insamo is positioned to make significant contributions to the pharmaceutical landscape, particularly in the realm of cyclic peptides.

United States

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding.

Insamo

Company Details